CLICK IMAGES TO DOWNLOAD REPORTS

IMMUNOGEN (IMGN): MIRVETUXIMAB SHOWS PROMISE IN 2ND LINE TREATMENT OF PLATINUM-RESISTANT OVARIAN CANCER 
​

NEKTAR THERAPEUTICS (NKTR): BEMPEGADESLEUKIN POTENTIAL 1ST LINE TREATMENT IN METASTATIC MELANOMA
​

UROGEN PHARMA (URGN): JELMYTO, TRANSFORMATIVE NON-SURGICAL TREATMENT OPTION IN BLADDER CANCER 
​

4Q19
EXELIXIS (EXEL): CABOZANTINIB IN RENAL CELL CARCINOMA 
​

MORPHOSYS (MOR): TAFASITAMAB AN EFFECTIVE TREATMENT OPTION IN R/R DLBCL
​

3Q19
NON-SMALL CELL LUNG CANCER (NSCLC) MARKET
​

3Q19
​SOLID TUMOR - GREATER ROLE FOR PARP INHIBITORS
​

3Q19
​COMPETITIVE POSITIONING IN HEMATOLOGIC CANCER - LYMPHOMA​

LARGE-CAP PHARMA/BIOTECH

Symbol
Manufacturer
Viola Advisory Rating
Viola Advisory PT
RHHBY
Roche
Buy
44.00
MRK
Merck & Co.
Buy
93.00
PFE
Pfizer Inc.
Buy
43.00
NVS
Novartis AG
Buy
100.00
AMGN
Amgen Inc.
Buy
235.00
BMY
Bristol-Myers
Buy
67.00
AZN
AstraZeneca plc
Buy
55.00
LLY
Eli Lilly and Co.
Buy
122.00
CLVS
Clovis Oncology
Hold
13.00
Source: Yahoo Finance, YCharts.com and Viola Advisory, LLC

BIOTECH SMIDs

Symbol
Manufacturer
Viola Advisory Rating
Viola Advisory PT
IONS
Ionis Pharmaceuticals
Buy
70.00
ALNY
Alnylam Pharmaceuticals
Hold
120.00
SRPT
Sarepta Therapeutics
Buy
140.00
NKTR
Nektar Therapeutics
Hold
25.00
SGEN
Seattle Genetics
Buy
125.00
IOVA
Iovance Biotherapeutics
Hold
30.00
Source: Yahoo Finance, YCharts.com and Viola Advisory, LLC

2Q19
IOVANCE BIOTHERAPEUTICS
​(IOVA)

2Q19
SEATTLE GENETICS
​(SGEN)​

1Q19
SANGAMO THERAPEUTICS
​(SGMO)

1Q19
IONIS PHARMACEUTICALS (IONS) &
​ALNYLAM PHARMACEUTICALS (ALNY)

1Q19
​SAREPTA
​THERAPEUTICS
​(SRPT)

1Q19
​NEKTAR
​THERAPEUTICS
​(NKTR)

PHARMA/BIOTECH
​4Q18 EARNINGS

PHARMA/BIOTECH INITIATION
​& 3Q18 EARNINGS

DRUG SUPPLY CHAIN

2Q18
​RETAIL PHARMACY/PBM

1Q18
​RETAIL PHARMACY/PBM

1Q18
​DRUG WHOLESALERS

1Q18
​HEALTH PAYERS

RETAIL PHARMACY INITIATION
​& 4Q17 EARNINGS

HEALTHCARE MERGERS (CVS/Aetna & Cigna/ESRX):
​PUTS & TAKES